Imc University Of Applied Sciences Krems
Imc University Of Applied Sciences Krems is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)
Sponsor Baxalta Innovations GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Vonicog Alfa (rVWF) in Children Diagnosed With Severe von Willebrand disease.
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed with Severe von Willebrand Disease
Sponsor Baxalta Innovations GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Imc University Of Applied Sciences Krems?
The 2026-10-09 snapshot links Imc University Of Applied Sciences Krems to 5 distinct CTIS trials. Recorded services include AAT function and antigen testing, ADA validation and testing, ADAMTS13 Activity, IgE Ab to VWF, ADAMTS13 Antigen, ADAMTS13 Inhibitory Ab (Dx),ADAMTS13 binding AB,ADAMTS13 activity, ADAMTS13 testing, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Imc University Of Applied Sciences Krems?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Blood Disorders, Respiratory. Recorded phases include Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Imc University Of Applied Sciences Krems conducted?
The linked trials record locations in 10 countries, including Spain, Italy, Austria, France, Poland. These are trial locations, not confirmed office locations or countries where Imc University Of Applied Sciences Krems delivered services.
What can this page tell me about Imc University Of Applied Sciences Krems's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Imc University Of Applied Sciences Krems. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Imc University Of Applied Sciences Krems